EPA:ALCLS - Euronext Paris - Matif - FR0010425595 - Common Stock - Currency: EUR
EPA:ALCLS (3/7/2025, 7:00:00 PM)
1.256
+0.05 (+4.32%)
The current stock price of ALCLS.PA is 1.256 EUR. In the past month the price decreased by -18.76%. In the past year, price decreased by -48.78%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B |
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 235 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
CELLECTIS
8, rue de la Croix Jarry
Paris ILE-DE-FRANCE FR
Employees: 219
Company Website: https://www.cellectis.com/
Investor Relations: https://www.cellectis.com/en/investors
Phone: 33181691600
The current stock price of ALCLS.PA is 1.256 EUR. The price increased by 4.32% in the last trading session.
The exchange symbol of CELLECTIS is ALCLS and it is listed on the Euronext Paris - Matif exchange.
ALCLS.PA stock is listed on the Euronext Paris - Matif exchange.
13 analysts have analysed ALCLS.PA and the average price target is 5.1 EUR. This implies a price increase of 306.05% is expected in the next year compared to the current price of 1.256. Check the CELLECTIS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CELLECTIS (ALCLS.PA) has a market capitalization of 125.72M EUR. This makes ALCLS.PA a Micro Cap stock.
CELLECTIS (ALCLS.PA) currently has 219 employees.
CELLECTIS (ALCLS.PA) has a resistance level at 1.75. Check the full technical report for a detailed analysis of ALCLS.PA support and resistance levels.
The Revenue of CELLECTIS (ALCLS.PA) is expected to grow by 169.93% in the next year. Check the estimates tab for more information on the ALCLS.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALCLS.PA does not pay a dividend.
CELLECTIS (ALCLS.PA) will report earnings on 2025-04-28, after the market close.
CELLECTIS (ALCLS.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.04).
ChartMill assigns a fundamental rating of 3 / 10 to ALCLS.PA. The financial health of ALCLS.PA is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ALCLS.PA reported a non-GAAP Earnings per Share(EPS) of -1.04. The EPS increased by 32.35% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -22.55% | ||
ROE | -61.78% | ||
Debt/Equity | 0.65 |
ChartMill assigns a Buy % Consensus number of 86% to ALCLS.PA. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 60.81% and a revenue growth 169.93% for ALCLS.PA